14F7 Biosimilar – Anti-ganglioside N-glycolyl GM3 mAb – Research Grade from ProteoGenix; catalogue PX-TA1072; research use only.
Know who made it. See the evidence. Buy through one marketplace.
14F7 Biosimilar is a monoclonal antibody (mAb) that specifically targets the ganglioside N-glycolyl GM3 (NeuGcGM3), a glycolipid that is highly expressed on the surface of cancer cells. This biosimilar is a research grade version of the 14F7 antibody, which has shown promising results in preclinical studies as a potential therapeutic agent for various types of cancer. In this article, we will explore the structure, activity, and potential applications of 14F7 Biosimilar in the field of cancer research.
14F7 Biosimilar is a recombinant humanized IgG1 monoclonal antibody that is produced in CHO (Chinese Hamster Ovary) cells. It has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains, connected by disulfide bonds. The antibody has a unique antigen-binding site that specifically recognizes the NeuGcGM3 antigen on the surface of cancer cells.
The main activity of 14F7 Biosimilar is its ability to bind to the NeuGcGM3 antigen and trigger an immune response against cancer cells. This is achieved through various mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. By targeting the NeuGcGM3 antigen, 14F7 Biosimilar can effectively inhibit the growth and spread of cancer cells, making it a promising therapeutic agent.
14F7 Biosimilar has shown potential as a therapeutic agent for various types of cancer, including melanoma, breast cancer, lung cancer, and neuroblastoma. Preclinical studies have demonstrated its efficacy in inhibiting tumor growth and metastasis, as well as improving survival rates in animal models. Additionally, 14F7 Biosimilar has been shown to enhance the effects of chemotherapy and radiation therapy when used in combination, making it a promising candidate for combination therapy in cancer treatment.
cancer therapies, 14F7 Biosimilar has several potential advantages. Firstly, it has a high specificity for the NeuGcGM3 antigen, which is highly expressed on the surface of cancer cells but not on normal cells. This reduces the risk of off-target effects and minimizes damage to healthy tissues. Secondly, as a biosimilar, it is a more cost-effective alternative to the original 14F7 antibody, making it more accessible for research and potential clinical use.
Despite its promising preclinical results, further research is needed to fully understand the potential of 14F7 Biosimilar as a therapeutic agent. Clinical trials are currently ongoing to evaluate its safety and efficacy in cancer patients. Additionally, further studies are needed to optimize its dosing and administration, as well as to explore its potential in combination with other anti- cancer therapies.
In summary, 14F7 Biosimilar is a research grade version of the 14F7 antibody that specifically targets the NeuGcGM3 antigen on the surface of cancer cells. Its unique structure and activity make it a promising therapeutic agent for various types of cancer. Ongoing research and clinical trials will further elucidate its potential and pave the way for its use in cancer treatment.
ProteoGenix catalogue number PX-TA1072. For research use only.
Target: 14F7 Biosimilar – Anti-ganglioside N-glycolyl GM3 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| 14F7 Biosimilar – Anti-ganglioside N-glycolyl GM3 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
